PRESS RELEASE
17 November 2026 17:11:00 CET

Cereno Scientific

Cereno Scientific announces resignation of Chairperson of the Board at his own request

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that Jeppe Øvlesen has informed the Board of Directors of his decision to resign as Chairperson and member of the Board at his own request, effective immediately.

“I have greatly valued my time as Chairperson of the Board of Cereno Scientific and the opportunity to work alongside Sten, his team and my fellow Board members. As the demands and responsibilities of the Chairperson role have increased, I have come to the conclusion that I am no longer best placed to fulfil the requirements of the position. I have therefore decided to step down. This decision does not change my confidence in the company’s science and the potential of its drug development programs. I wish Cereno and its team every success going forward,” said Jeppe Øvlesen.

“We respect Jeppe’s decision and thank him for his contributions and commitment during his time on the Board. We wish him every success in his future endeavors. Our focus remains on advancing Cereno’s drug development programs and executing our financing plans to support the company’s continued development,” said Sten R. Sörensen, CEO of Cereno Scientific.

According to Cereno Scientific’s Articles of Association, the Board of Directors shall consist of a minimum of four and a maximum of eight members. Following Jeppe Øvlesen’s resignation, the Board will consist of four members and will therefore continue to comply with the requirements of the Articles of Association. The Board will announce its designated Chairperson as soon as possible.

For further information, please contact:
Tove Bergenholt, Head of IR & Communications
Email: **tove.bergenholt@cerenoscientific.com**
Phone: +46 73- 236 62 46

This information is information that Cereno Scientific is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-17 17:11 CET.

Cereno Scientific

About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the underlying mechanisms of pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class, risk score and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program confirmed CS1 to be well-tolerated with a favorable safety profile over 12 months of treatment and showed that a majority of patients completing treatment maintained or improved clinical status. CS1 is currently being evaluated in EPIMODE, a global, placebo-controlled Phase IIb trial in PAH. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed a favorable safety and tolerability profile in Phase I, and is being advanced through a streamlined, FDA-aligned pathway toward Phase IIb in pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also advancing the preclinical program CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist shown to prevent thrombosis without increased bleeding risk, currently being evaluated in antiphospholipid syndrome (APS).

The Company is headquartered in GoCo Health Innovation City in Gothenburg, Sweden, and has a US subsidiary, Cereno Scientific Inc., located in Kendall Square, Boston. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, **certifiedadviser@carnegie.se**. More information can be found on **www.cerenoscientific.com**.